Respiratory adverse-event signals of four Bruton tyrosine kinase inhibitors: cross-database replication and temporal characterization in FAERS and JADER. [PDF]
Zheng Z, Zhao F, Zhao Z, Jin P.
europepmc +1 more source
The place of acalabrutinib-obinutuzumab combination in the first-line treatment of patients with chronic lymphocytic leukemia. [PDF]
Szymczyk A, Hus I.
europepmc +1 more source
Outcomes of Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors (BTKi): A Retrospective Study From a Tertiary Healthcare Center in North India. [PDF]
Shukla A +7 more
europepmc +1 more source
Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report. [PDF]
Shakarchi FF +5 more
europepmc +1 more source
Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. [PDF]
Xu F, Zou X, Yang Y, Zhou K, Huang W.
europepmc +1 more source
Comment on "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation". [PDF]
Tedeschi A +12 more
europepmc +1 more source
A prospective, multi-center, phase IV clinical study to assess the safety and clinical outcome of acalabrutinib in Indian adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory mantle cell lymphoma. [PDF]
Malhotra P +15 more
europepmc +1 more source
Cardiac adverse event signals of Bruton's tyrosine kinase inhibitors as primary suspect and in co-reported regimens: a large-scale FAERS pharmacovigilance study. [PDF]
Zhang T, Wang G, Yang X, Li L, Song D.
europepmc +1 more source
Peripheral and central nervous system toxicities of Bruton tyrosine kinase Inhibitors: a real-world pharmacovigilance study. [PDF]
Zhang J.
europepmc +1 more source
Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia. [PDF]
Hou JZ +16 more
europepmc +1 more source

